A randomized, crossover study to evaluate the impact of gastric acid reducing agents on pharmacokinetics of Sofosbuvir/Velpatasvir/Voxilaprevir fixed dose combination tablet.

Trial Profile

A randomized, crossover study to evaluate the impact of gastric acid reducing agents on pharmacokinetics of Sofosbuvir/Velpatasvir/Voxilaprevir fixed dose combination tablet.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary) ; Famotidine; Omeprazole
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 29 Mar 2018 New trial record
    • 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top